A new anti-cancer compound that works by blocking a part of the cell’s machinery that is crucial for cell division has shown promising results in a phase I clinical trial in patients who have failed to respond to other treatments.
A new anti-cancer compound that works by blocking a part of the cell’s machinery that is crucial for cell division has shown promising results in a phase I clinical trial in patients who have failed to respond to other treatments.